Tempest Therapeutics
TPST
51 hedge funds and large institutions have $14.8M invested in Tempest Therapeutics in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 11 increasing their positions, 18 reducing their positions, and 29 closing their positions.
108% more call options, than puts
Call options by funds: $410K | Put options by funds: $197K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less funds holding
Funds holding: 61 → 51 (-10)
34% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 29
39% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 18
78% less capital invested
Capital invested by funds: $66.6M → $14.8M (-$51.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$795K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$534K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$517K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$369K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$336K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$7.37M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$4.4M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.97M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.64M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.14M |
TPST Hedge Fund Activity: Q2 2020 in Review
51 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2020, worth a combined $14.8M — down 78% from $66.6M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of TPST and 19 opened new positions — a net loss of 10 holders — while 18 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, adding an estimated $795K. The largest seller was Frazier Management, exiting entirely with an estimated $7.37M sold.
- 51 institutional investors held Tempest Therapeutics (TPST) as of Q2 2020, down from 61 in Q1 2020.
- Funds reported $14.8M of Tempest Therapeutics stock for Q2 2020, down 78% quarter-over-quarter.
- 19 funds opened new Tempest Therapeutics positions in Q2 2020 and 29 closed out, a net change of -10 holders.
- The largest Tempest Therapeutics buyer in Q2 2020 was Renaissance Technologies, an estimated $795K added.
- The largest Tempest Therapeutics seller in Q2 2020 was Frazier Management, an estimated $7.37M sold.
Based on aggregated 13F filings for Q2 2020.